AeroCyte

AeroCyte is a pre-clinical stage biotechnology company focused on the development of aerosolized cell therapies for the treatment of chronic and acute lung diseases. Spun out from the University of North Carolina at Chapel Hill, the company's proprietary platform enables the non-invasive delivery of therapeutic cells, such as stem cells or engineered cells, directly to the respiratory tract via inhalation. By bypassing systemic circulation, AeroCyte aims to increase the local concentration of therapeutic agents in the lungs while minimizing systemic side effects. The company's research targets high-unmet-need indications including Cystic Fibrosis, COPD, and Acute Respiratory Distress Syndrome (ARDS).